Patient Advocacy Summit 2019

November 6, 2019 8:00 AM - 4:30 PM

Marriott Boston Cambridge, 50 Broadway, Cambridge, Massachusetts 02142 USA

Add to Calendar 11/6/2019 8:00:00 AM 11/6/2019 4:30:00 PM Patient Advocacy Summit 2019

MassBio's Patient Advocacy Summit brings together the patient advocacy community to showcase best practices and cutting-edge examples of how life sciences companies can more fully incorporate the patient voice into the work they do—not just approaching regulatory applications or at commercialization, but throughout the drug development cycle.

This year we'll explore competing views on what value therapies bring to various stakeholders, what a cure is worth to patients and society, how to improve the clinical trial experience for patients, and more. We will also have a frank discussion about patient access in the era of transformative therapies, and you’ll hear directly from patients on what this means to them.

The program includes panel discussions, case study presentations(spotlighting industry/patient partnerships), an inspirational keynote address, as well as a networking lunch and cocktail reception.

See sponsorship opportunities here, or contact Laura Rudberg.

 Marriott Boston Cambridge, 50 Broadway, Cambridge, Massachusetts 02142 USA
Senior Manager, Clinical Science & Biomarker Development, Ra Pharma
Michelle began working at Ra Pharma in 2011 as an assay development scientist in the Target Biology group. Michelle’s initial role in the company was to design and perform the cell-based and biochemical assays needed for all projects. As Ra Pharma grew and identified a lead project, Michelle’s role grew to developing the pharmacodynamic assays needed for the animal studies. She then went on to design and oversee the validation of these assays for use in human clinical trials. Michelle’s career at Ra Pharma transitioned into the Translational Sciences group and now into the Clinical Development group where she is the Senior Manager for Clinical Science & Biomarker Development. Michelle is currently responsible for the pharmacodynamic, pharmacokinetic, pharmacogenomic and biomarker data across all completed and current Phase 1, Phase 2 and Phase 3 clinical trials at Ra Pharma for their C5 inhibitor, zilucoplan.

Brought to you by